182 related articles for article (PubMed ID: 9322393)
1. Virus-specific cytotoxic T lymphocytes as prophylaxis for Epstein-Barr virus lymphoproliferative disease in pediatric bone marrow transplant recipients.
Norville R; Nance D; Cheshire S
J Pediatr Oncol Nurs; 1997 Oct; 14(4):194-201. PubMed ID: 9322393
[TBL] [Abstract][Full Text] [Related]
2. Production of genetically modified Epstein-Barr virus-specific cytotoxic T cells for adoptive transfer to patients at high risk of EBV-associated lymphoproliferative disease.
Smith CA; Ng CY; Heslop HE; Holladay MS; Richardson S; Turner EV; Loftin SK; Li C; Brenner MK; Rooney CM
J Hematother; 1995 Apr; 4(2):73-9. PubMed ID: 7633844
[TBL] [Abstract][Full Text] [Related]
3. Unsuccessful CTL transfusion in a case of post-BMT Epstein-Barr virus-associated lymphoproliferative disorder (EBV-LPD).
Imashuku S; Goto T; Matsumura T; Naya M; Yamori M; Hojo M; Hibi S; Todo S
Bone Marrow Transplant; 1997 Aug; 20(4):337-40. PubMed ID: 9285550
[TBL] [Abstract][Full Text] [Related]
4. Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells.
Gustafsson A; Levitsky V; Zou JZ; Frisan T; Dalianis T; Ljungman P; Ringden O; Winiarski J; Ernberg I; Masucci MG
Blood; 2000 Feb; 95(3):807-14. PubMed ID: 10648390
[TBL] [Abstract][Full Text] [Related]
5. The development of cellular immunity to Epstein-Barr virus after allogeneic bone marrow transplantation.
Lucas KG; Small TN; Heller G; Dupont B; O'Reilly RJ
Blood; 1996 Mar; 87(6):2594-603. PubMed ID: 8630428
[TBL] [Abstract][Full Text] [Related]
6. Duration of Epstein-Barr virus (EBV)-associated polyclonal lymphoproliferative disease (LPD) following bone marrow transplantation.
Imashuku S; Iwami H; Tsunamoto K; Hibi S; Todo S
Bone Marrow Transplant; 1996 Oct; 18(4):823-4. PubMed ID: 8899207
[No Abstract] [Full Text] [Related]
7. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation.
Rooney CM; Smith CA; Ng CY; Loftin S; Li C; Krance RA; Brenner MK; Heslop HE
Lancet; 1995 Jan; 345(8941):9-13. PubMed ID: 7799740
[TBL] [Abstract][Full Text] [Related]
8. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation.
Papadopoulos EB; Ladanyi M; Emanuel D; Mackinnon S; Boulad F; Carabasi MH; Castro-Malaspina H; Childs BH; Gillio AP; Small TN
N Engl J Med; 1994 Apr; 330(17):1185-91. PubMed ID: 8093146
[TBL] [Abstract][Full Text] [Related]
9. Low-dose interleukin 2 prevents the development of Epstein-Barr virus (EBV)-associated lymphoproliferative disease in scid/scid mice reconstituted i.p. with EBV-seropositive human peripheral blood lymphocytes.
Baiocchi RA; Caligiuri MA
Proc Natl Acad Sci U S A; 1994 Jun; 91(12):5577-81. PubMed ID: 7911241
[TBL] [Abstract][Full Text] [Related]
10. Antiviral prophylaxis and the Epstein Barr virus-related post-transplant lymphoproliferative disorder.
Davis CL; Harrison KL; McVicar JP; Forg PJ; Bronner MP; Marsh CL
Clin Transplant; 1995 Feb; 9(1):53-9. PubMed ID: 7742583
[TBL] [Abstract][Full Text] [Related]
11. Early identification of Epstein-Barr virus-associated post-transplantation lymphoproliferative disease.
Rooney CM; Loftin SK; Holladay MS; Brenner MK; Krance RA; Heslop HE
Br J Haematol; 1995 Jan; 89(1):98-103. PubMed ID: 7833284
[TBL] [Abstract][Full Text] [Related]
12. Semiquantitative Epstein-Barr virus (EBV) polymerase chain reaction for the determination of patients at risk for EBV-induced lymphoproliferative disease after stem cell transplantation.
Lucas KG; Burton RL; Zimmerman SE; Wang J; Cornetta KG; Robertson KA; Lee CH; Emanuel DJ
Blood; 1998 May; 91(10):3654-61. PubMed ID: 9573001
[TBL] [Abstract][Full Text] [Related]
13. Administration of neomycin-resistance-gene-marked EBV-specific cytotoxic T lymphocytes to recipients of mismatched-related or phenotypically similar unrelated donor marrow grafts.
Heslop HE; Brenner MK; Rooney C; Krance RA; Roberts WM; Rochester R; Smith CA; Turner V; Sixbey J; Moen R
Hum Gene Ther; 1994 Mar; 5(3):381-97. PubMed ID: 8018749
[No Abstract] [Full Text] [Related]
14. Immunotherapy for Epstein-Barr virus-associated cancers.
Rooney CM; Roskrow MA; Smith CA; Brenner MK; Heslop HE
J Natl Cancer Inst Monogr; 1998; (23):89-93. PubMed ID: 9709309
[TBL] [Abstract][Full Text] [Related]
15. Epstein-Barr virus-associated lymphoproliferative disorder after unrelated bone marrow transplantation in a young child with Wiskott-Aldrich syndrome.
Sasahara Y; Kawai S; Itano M; Kumaki S; Fujie H; Minegishi M; Tsuchiya S; Konno T
Pediatr Hematol Oncol; 1998; 15(4):347-52. PubMed ID: 9658436
[TBL] [Abstract][Full Text] [Related]
16. Epstein-Barr virus-associated B cell lymphoproliferative disorder following mismatched related T cell-depleted bone marrow transplantation.
Chiang KY; Hazlett LJ; Godder KT; Abhyankar SH; Christiansen NP; van Rhee F; Lee CG; Bridges K; Parrish RS; Henslee-Downey PJ
Bone Marrow Transplant; 2001 Dec; 28(12):1117-23. PubMed ID: 11803352
[TBL] [Abstract][Full Text] [Related]
17. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes.
Heslop HE; Ng CY; Li C; Smith CA; Loftin SK; Krance RA; Brenner MK; Rooney CM
Nat Med; 1996 May; 2(5):551-5. PubMed ID: 8616714
[TBL] [Abstract][Full Text] [Related]
18. Epstein-Barr virus-associated lymphoproliferative disease after allogeneic haematopoietic stem cell transplantation: molecular monitoring and early treatment of high-risk patients.
Meijer E; Cornelissen JJ
Curr Opin Hematol; 2008 Nov; 15(6):576-85. PubMed ID: 18832928
[TBL] [Abstract][Full Text] [Related]
19. Epstein-Barr virus-specific T-cell cytotoxicity is mediated through the perforin pathway in patients with lymphoproliferative disorders after allogeneic bone marrow transplantation.
Yoshimi A; Tsuge I; Namizaki H; Hoshino Y; Kimura H; Takahashi Y; Watanabe N; Kuzushima K; Kojima S
Br J Haematol; 2002 Mar; 116(3):710-5. PubMed ID: 11849237
[TBL] [Abstract][Full Text] [Related]
20. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the prevention and treatment of EBV-associated post-transplant lymphomas.
Liu Z; Savoldo B; Huls H; Lopez T; Gee A; Wilson J; Brenner MK; Heslop HE; Rooney CM
Recent Results Cancer Res; 2002; 159():123-33. PubMed ID: 11785836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
